Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Organon & Co. regarding a class action lawsuit due to misleading statements and a significant reduction in quarterly dividends, which led to a sharp decline in stock price [1][3]. Summary by Sections Class Action Details - Shareholders who purchased Organon shares between October 31, 2024, and April 30, 2025, are encouraged to contact the firm for potential lead plaintiff appointment [1][4]. - The allegations include that the defendants made overly positive statements while concealing adverse facts about Organon's capital allocation priorities, particularly regarding debt reduction after the acquisition of Dermavant [3]. Financial Impact - Following the revelation of the debt reduction strategy, Organon's regular quarterly dividend was reduced by 70%, causing the stock price to drop from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, representing a decline of over 27% in one day [3]. Next Steps for Shareholders - The deadline for shareholders to register for the class action is July 22, 2025, and there is no cost or obligation to participate [4]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [5].

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for alleged violations of the Securities Exchange Act of 1934, claiming misleading statements regarding the company's financial health and projections during the Class Period from November 3, 2022, to April 30, 2025 [1][4]. Company Allegations - The lawsuit alleges that Organon misrepresented the risk of loss of exclusivity and price erosion for its product Nexplanon, leading to inflated sales growth expectations that would not reach the projected $1 billion by the end of fiscal year 2025 [4]. - It is claimed that Organon was not on track to achieve the necessary $1 billion in free cash flow to sustain its dividend, nor maintain a debt leverage ratio of 4.0x, which could jeopardize its corporate debt ratings [4]. - The lawsuit also states that Organon lacked a reasonable basis for reporting its business metrics and financial projections during the Class Period [4]. Financial Impact - Following the announcement of its first quarter 2025 financial results, Organon reduced its dividend by 90%, from $1.16 per share annually to $0.08 per share annually, which resulted in a stock price drop of over 27% [5].

NEW YORK, July 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Organon & Co. (NYSE: OGN).Shareholders who purchased shares of OGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/organon-co-loss-submission-form/?id=156033&from=4CLASS PERIOD: October 31, 2024 to April 30, 20 ...

Core Viewpoint - A lawsuit has been filed against Organon & Co. and its senior executives for potential violations of federal securities laws, particularly related to misleading statements about the company's dividend policy following a significant acquisition [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, titled Hauser v. Organon & Co., et al., No. 25-cv-05322, and investors have until July 22, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Organon securities [2]. Group 2: Company Background and Acquisition - Organon is a global healthcare company focused on women's health, known for rewarding shareholders with dividends [3]. - In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company, which increased its debt [3]. Group 3: Dividend Policy and Stock Performance - Following the acquisition, Organon assured investors it would maintain its dividend, claiming it was the "1 capital allocation priority," but later shifted focus to debt reduction, leading to a significant dividend cut [3]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 per share to $0.02 per share, resulting in a stock price decline of approximately 27%, from $12.93 to $9.45 per share [4].

Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for alleged misrepresentations regarding its capital allocation and sales growth of its product Nexplanon during the class period from November 3, 2022, to April 30, 2025 [1][4]. Group 1: Lawsuit Details - The lawsuit claims that despite acquiring Dermavant for $1.2 billion, Organon assured investors it would maintain its dividend as its top capital allocation priority, which was later shifted to debt reduction [2][3]. - Allegations include failure to disclose risks related to Nexplanon, leading to overestimated sales growth projections and the likelihood of not achieving a $1 billion milestone payment from Merck & Co. [4]. Group 2: Financial Impact - On May 1, 2025, Organon announced a significant reduction in its dividend payout from $0.28 per share to $0.02 per share, causing its stock price to drop by approximately 27%, from $12.93 to $9.45 per share [5].

Core Viewpoint - ClaimsFiler informs investors about the deadline to file lead plaintiff applications in securities class action lawsuits against Organon & Co. for the Class Period from October 31, 2024, to April 30, 2025 [1] Group 1: Lawsuit Details - Organon and certain executives are accused of failing to disclose material information during the Class Period, violating federal securities laws [3] - The first-filed case is Hauser v. Organon & Co., et al., and a subsequent case, Lerner v. Organon & Co., et al., expanded the class period [5] Group 2: Financial Impact - On March 10, 2025, Organon announced a significant reduction in its dividend payout from $0.28 to $0.02, which contradicted previous assurances to investors [4] - Following the dividend announcement, Organon's share price dropped over 27%, from $12.93 on April 30, 2025, to $9.45 on May 1, 2025 [4] Group 3: Investor Support - ClaimsFiler provides resources for investors to recover funds from securities class action settlements, including free registration for information access and case evaluations [6]

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for alleged violations of the Securities Exchange Act of 1934, claiming misleading statements regarding the company's financial health and projections during the Class Period from November 3, 2022, to April 30, 2025 [1][4]. Company Overview - Organon develops and delivers health solutions through prescription therapies and medical devices [3]. Allegations of the Lawsuit - The lawsuit alleges that Organon misrepresented the risk of loss of exclusivity and price erosion for its product Nexplanon, leading to inflated sales growth expectations that would not reach $1 billion by the end of fiscal year 2025 [4]. - It is claimed that Organon was not on track to achieve a $1 billion milestone payment from Merck & Co. related to Nexplanon sales, nor maintain the required $1 billion in free cash flow to sustain its dividend [4]. - The lawsuit further asserts that Organon might not maintain its corporate debt ratings and lacked a reasonable basis for reporting its business metrics and financial projections during the Class Period [4]. Financial Impact - Following the announcement of its first quarter 2025 financial results, Organon reduced its dividend by 90%, from $1.16 per share annually to $0.08 per share annually, which resulted in a stock price drop of over 27% [5].

Core Viewpoint - A class action securities lawsuit has been filed against Organon & Co. for alleged securities fraud affecting investors between October 31, 2024, and April 30, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Organon's management made overly positive statements while concealing material adverse facts about the company's capital allocation priorities, particularly regarding a significant debt reduction strategy following the acquisition of Dermavant [2]. - As a result of these actions, Organon reduced its regular quarterly dividend by 70%, leading to a dramatic decline in stock price from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, representing a drop of over 27% in just one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until July 22, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/organon-co-class-action. Investors have until July 22, 2025, to ask the Court to be appointed to lea ...

在全球，大概每10个育龄女性中就有1个饱受子宫内膜异位症的折磨——这是一种影响约1.9亿女性的高 发疾病，90%的患者经历着间断性的盆腔疼痛，26%甚至面临不孕的阴影。 然而，当Organon近日宣布其"明星候选药物"OG-6219在二期临床试验中宣告失败时，这个本应充满希 望的领域再次被蒙上阴霾。 OG-6219曾被寄予厚望，被Organon视为"重塑痛经治疗标准"的突破，但它的失败不仅让Organon的女性 健康创新管线陷入危机，更揭示了子宫内膜异位症药物研发的深层困境： 一个影响数亿人的市场，为何新药寥寥无几？痛经药物的春天究竟何时才能到来？ 01 需求巨大，供给稀缺 痛经，尤其严重的痛经，很可能是一种病——子宫内膜异位症。子宫内膜异位症远不止痛经那么简单， 不仅可以侵袭周围组织和其他器官，导致复杂的症状，还容易在治疗后反复发作，直到绝经后才能缓 解，给患者带来无尽的痛苦折磨。 理论上，子宫内膜异位症拥有巨大的治疗需求与商业空间，但现实却是新药稀缺，研发缓慢。 更早前，拜耳也曾布局这一领域，其靶向孕激素/催乳素（ER/PR）药物Visanne于2010年首次在欧洲获 批，用于治疗子宫内膜异位症引发的疼痛 ...